DividendMapper
Royalty Pharma plc logo

RPRX

Royalty Pharma plc

  • Healthcare
  • US companies in Healthcare (47)
  • NASDAQ · USD
  • Mkt cap $29.4bn

$65.93

as of 29 Oct 2026, 1% below its 52-week high

Screens as reasonably placed to keep growing its dividend, with low cut-risk signals. Its valuation looks somewhat extended against its own history.

These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.

Trailing yield
1.40%Last 12 months of regular payments at today's price
Forward yield
1.48%Each payment expected in the next 12 months, not the latest one doubled
Earnings cover
2.0×Pays 49% of earnings
Cash cover
7.5×Free cash flow over dividends paid
5y dividend growth
Not availableNo cut since FY2022
Next ex-dividend date
Declared13 Nov 2026Quarterly dividend of $0.24

Compared with US companies in Healthcare (47)

  • Trailing yield is higher than 30 of the 46 other US companies in Healthcare.

Quality

72

Moderate

Capacity to keep growing the dividend

Risk

25

Low

Signals of dividend-cut pressure

Trim

70

Moderate

How extended the valuation looks

Why Quality is 72

RPRX against US companies in Healthcare (47)

Valuation against its own history

As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of RPRX’s past readings.

  • P/E30.6×P77, poor for this measure
  • Yield1.62%P18, poor for this measure
  • FCF payout13.4%P27, good for this measure
  • Net debt / EBITDA4.75P65, neutral for this measure
  • DGR 5y+7.3%P6, poor for this measure
  • ROIC8.4%P35, neutral for this measure
Open valuation history

Forecast your income with the RPRX dividend calculator

Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.